New hope for lung cancer patients whose tumor type shifts
NCT ID NCT05957510
First seen Apr 07, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer changed from one type (EGFR-mutated non-small cell) to another (small cell) after prior treatment. About 66 adults aged 18-75 will take part. The goal is to see if this combo can shrink tumors or slow the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Perople's Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.